Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Greil

Showing results (111-120 of 145) with videos related to

Pageof 15
Sort By:
British Journal of Cancer|July 23, 2013
The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trialM Gnant, G Pfeiler, H Stöger, et al.
Leukemia|November 3, 2015
CD4+ T cells, but not non-classical monocytes, are dispensable for the development of chronic lymphocytic leukemia in the TCL1-tg murine modelT Kocher, D Asslaber, N Zaborsky, et al.
British Journal of Cancer|September 27, 2007
A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancerW Schippinger, H Samonigg, R Schaberl-Moser, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 23, 2008
A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclinesP Schmid, D Kühnhardt, P Kiewe, et al.
British Journal of Cancer|September 30, 2010
Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive valueA Michlmayr, T Bachleitner-Hofmann, S Baumann, et al.
Blood|December 15, 1995
Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of responseM Cazzola, D Messinger, V Battistel, et al.
Annals of Hematology|December 3, 2013
Alemtuzumab in chronic lymphocytic leukemia: final results of a large observational multicenter study in mostly pretreated patientsM Fiegl, R Stauder, M Steurer, et al.
ESMO Open|January 5, 2021
A clinical validation study of MammaPrint in hormone receptor-positive breast cancer from the Austrian Breast and Colorectal Cancer Study Group 8 (ABCSG-8) biomarker cohortP Dubsky, L Van't Veer, M Gnant, et al.
Leukemia|January 21, 2014
Targeting proliferation of chronic lymphocytic leukemia (CLL) cells through KCa3.1 blockadeE M Grössinger, L Weiss, S Zierler, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 4, 2015
Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtypeM Gnant, I Sestak, M Filipits, et al.
Pageof 15

Showing results (111-120 of 145) with videos related to

Sort By:
Pageof 15
British Journal of Cancer|July 23, 2013
The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trialM Gnant, G Pfeiler, H Stöger, et al.
Leukemia|November 3, 2015
CD4+ T cells, but not non-classical monocytes, are dispensable for the development of chronic lymphocytic leukemia in the TCL1-tg murine modelT Kocher, D Asslaber, N Zaborsky, et al.
British Journal of Cancer|September 27, 2007
A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancerW Schippinger, H Samonigg, R Schaberl-Moser, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 23, 2008
A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclinesP Schmid, D Kühnhardt, P Kiewe, et al.
British Journal of Cancer|September 30, 2010
Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive valueA Michlmayr, T Bachleitner-Hofmann, S Baumann, et al.
Blood|December 15, 1995
Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of responseM Cazzola, D Messinger, V Battistel, et al.
Annals of Hematology|December 3, 2013
Alemtuzumab in chronic lymphocytic leukemia: final results of a large observational multicenter study in mostly pretreated patientsM Fiegl, R Stauder, M Steurer, et al.
ESMO Open|January 5, 2021
A clinical validation study of MammaPrint in hormone receptor-positive breast cancer from the Austrian Breast and Colorectal Cancer Study Group 8 (ABCSG-8) biomarker cohortP Dubsky, L Van't Veer, M Gnant, et al.
Leukemia|January 21, 2014
Targeting proliferation of chronic lymphocytic leukemia (CLL) cells through KCa3.1 blockadeE M Grössinger, L Weiss, S Zierler, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 4, 2015
Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtypeM Gnant, I Sestak, M Filipits, et al.
Pageof 15